Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

globenewswire.com
ALXO The article announces ALX Oncology's participation in upcoming investor conferences in Q1 2026. This is a routine corporate event and does not provide new information about the company's performance or prospects, hence the neutral sentiment.

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit.

The details of the meetings are as follows:

Wells Fargo Executive Biotech Summit

Format: One-on-one meetings

Date: February 24-25, 2026

Location: Lake Tahoe, CA

TD Cowen 46th Annual Health Care Conference

Format: Presentation

Date: March 3, 2026

Time: 9:10 AM EST

Location: Boston, MA

Webcast link: Available here

UBS Biotech Summit

Format: One-on-one meetings

Date: March 10, 2026

Location: Miami, FL

The webcast of the TD Cowen 46th Annual Health Care Conference presentation can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. Replay of the webcast will be archived for up to 90 days following the presentation date.

About ALX Oncology

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1 dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:

Elhan Webb, CFA, IR Consultant

ewebb@alxoncology.com

Media Contact:

Michele Parisi, SparkPoint Healthcare Communications

mparisi@sparkpointpr.com

(925) 864-5028